AACC uses cookies to ensure the best website experience. Continuing without changing cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


Features


Defining “normal” requires scientific evidence that demonstrates what healthy levels are for a range of chemicals in the body for different populations. This is especially challenging to accomplish for children.
This article provides an update on the current treatment options available and the current laboratory methods used to monitor patients with Sickle Cell Disease.
For decades, body fluid testing has been a routine practice within clinical laboratories both large and small, and in the past 10−15 years especially, major strides have been made in understanding the practicalities of testing these fluids.

Ask the Expert


FibroTest-ActiTest and NASH-FibroTest are proprietary algorithms that utilize the patient’s age and sex along with measurement of serum biomarkers to estimate liver fibrosis/cirrhosis, necroinflammatory activity, steatosis, and non-alcoholic steatohepatitis (NASH).

Bench Matters


Federal Insider


Even as a Senate committee has voted to include the VALID Act within a larger medical device user fee bill, the FDASLA Act, more than 100 medical and patient organizations have joined AACC in calling out problems with provisions in the bill.

Laboratory Stewardship


In the ammonia paradox, measuring ammonia levels in confused cirrhotic patients with hepatic encephalopathy is, to paraphrase Adrian Reuben, MD, an action that creates greater confusion in those ordering the test than the confusion present in the patient.

Regulatory Roundup


Special Supplement


The Sample